fintols

Eli Lilly vs Novo Nordisk (LLY vs NVO)

Novo Nordisk trades at 10.0x earnings vs 44.9x for Eli Lilly; Eli Lilly grows sales faster (+38.6% vs +5.6%). Margins, debt and dividend, Nov 2026.

Quick answer

On today's data (November 19, 2026): Novo Nordisk looks cheaper on P/E: 10.0x against 44.9x for Eli Lilly. Eli Lilly grows faster: sales +38.6% against +5.6% for Novo Nordisk in the latest quarter. Novo Nordisk has the better net margin: 33.9% against 31.9% for Eli Lilly.

This is a snapshot of the numbers, not a recommendation to buy or sell.

Analyze Eli Lilly freeAnalyze Novo Nordisk free

Your first analysis is free with a free account, no card.

Short answer

On P/E as of November 19, 2026, Eli Lilly is the more expensive of the two: it trades at 44.9x its annual earnings against 10.0x for Novo Nordisk. Eli Lilly sells prescription medicines. Its largest revenue source is tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, followed by Verzenio for breast cancer, Jardiance and Trulicity for diabetes, Taltz for immunology and Kisunla for Alzheimer's disease. Danish drugmaker Novo Nordisk reports two segments: Diabetes and Obesity care, its largest, with insulins and the drugs Ozempic, Rybelsus and Wegovy; and Rare Disease, with treatments for hemophilia and growth disorders. What helps read that gap: Eli Lilly sales +38.6% against +5.6% for Novo Nordisk in the latest quarter; net margin 31.9% against 33.9%; net debt for Eli Lilly: 1.0x EBITDA against 0.5x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.

Eli Lilly (LLY) and Novo Nordisk (NVO) compete in healthcare and pharma. Here are Eli Lilly and Novo Nordisk side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Eli Lilly or Novo Nordisk.

Eli Lilly vs Novo Nordisk: the figures

FigureEli LillyNovo Nordisk
Share price$1,382.75 (November 18, 2026)$39.43 (November 18, 2026)
Market cap$1.23 trillion$173.8 billion
P/E (TTM)44.9x10.0x
Forward P/E27.2x1.7x
Revenue growth (quarter)+38.6%+5.6%
Net margin (TTM)31.9%33.9%
Net debt / EBITDA1.0x0.5x
Dividend yield0.50%4.56%
Beta0.390.37

Eli Lilly and Novo Nordisk figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Eli Lilly or Novo Nordisk figure is not available, and we never estimate it.

3 key differences between Eli Lilly and Novo Nordisk

  1. Valuation: Eli Lilly trades at 44.9x its annual earnings and Novo Nordisk at 10.0x; the market pays more for each dollar of Eli Lilly profit, usually because it expects more growth.
  2. Growth: Eli Lilly grew sales +38.6% year on year in its latest quarter, against +5.6% for Novo Nordisk.
  3. Dividend: Novo Nordisk yields 4.56% at today's price and Eli Lilly yields 0.50%.

Eli Lilly or Novo Nordisk: which fits your profile

Neither Eli Lilly nor Novo Nordisk wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

Verdict: Eli Lilly or Novo Nordisk?

Of the 6 comparable figures in the table, Eli Lilly stands out on 1 (sales growth) and Novo Nordisk stands out on 5 (net margin, lower P/E, dividend yield, less debt over EBITDA and lower volatility (beta)). That does not name a winner between Eli Lilly and Novo Nordisk: the table is a snapshot of today, not a forecast.

You are halfway through

Keep reading free.

Create your free account to continue reading “Eli Lilly vs Novo Nordisk (LLY vs NVO)”.

No card required

That easy

Three steps. Zero spreadsheets.

  1. 1Search a companyBy the name you know it: Apple, Inditex, Santander… ETFs too.
  2. 2Fintols does the homeworkIt reads the official filings, runs the numbers and writes the analysis for you.
  3. 3You analyze and decideWith the five answers clear, you decide. And you save the analysis to review it when the price moves.
Analyze any stock free
Analyze LLY free